急性缺血性卒中超过常规时间窗的静脉溶栓:系统评价与荟萃分析
该系统评价与荟萃分析纳入14项RCT、共4174例发病≥4.5小时的急性缺血性卒中患者,比较静脉溶栓与安慰剂或标准内科治疗。溶栓组90天极好功能预后(mRS 0-1)RR 1.22(95%CI 1.14-1.31)、良好功能预后(mRS 0-2)RR 1.12(95%CI 1.06-1.18)均显著提高,90天全因死亡率无差异(RR 1.13;95%CI 0.93-1.38),但症状性颅内出血风险增加(RR 2.44;95%CI 1.45-4.09),NNT 12-16、NNH 62。结论支持在经适当影像筛选的患者中将溶栓时间窗扩展至4.5小时以外。
要点
- 发病≥4.5小时经影像筛选的急性缺血性卒中患者,静脉溶栓使90天极好功能预后(mRS 0-1)RR 1.22(95%CI 1.14-1.31)。
- 同一人群90天良好功能预后(mRS 0-2)RR 1.12(95%CI 1.06-1.18),额外获得1例良好预后需治疗12-16例。
- 溶栓组症状性颅内出血风险显著升高,RR 2.44(95%CI 1.45-4.09),每62例治疗额外增加1例症状性颅内出血。
- 90天全因死亡率两组无差异,RR 1.13(95%CI 0.93-1.38)。
- 结论支持对经适当影像筛选的患者将静脉溶栓时间窗扩展至4.5小时以外。
适用人群与场景
- 成人急性缺血性卒中患者,发病4.5小时或更长时间后接受静脉溶栓者,或发病时间未知者。
- 纳入标准为比较溶栓与安慰剂或标准内科治疗、报告功能或安全结局的RCT。
诊断标准与关键阈值
- 常规静脉溶栓时间窗为症状发作4.5小时内,超窗定义为发病4.5小时或更长时间。
- 功能结局采用90天改良Rankin量表(mRS)评分:极好功能预后为mRS 0-1,良好功能预后为mRS 0-2。
- 原文提及影像筛选患者,但未给出具体影像标准或界值。
处置流程与药物剂量
- 对发病4.5小时或更长时间、经适当影像筛选的急性缺血性卒中患者,可考虑静脉溶栓以改善功能预后。
- 原文未提及具体溶栓药物名称、剂量、给药途径、频次或疗程。
- 治疗决策需权衡功能获益(NNT 12-16)与症状性颅内出血风险(NNH 62)。
红旗征与不能漏的情况
- 症状性颅内出血风险增加(RR 2.44;95%CI 1.45-4.09),溶栓后需警惕并监测。
研究设计与关键结果
- 研究类型为系统评价与荟萃分析,纳入14项RCT、共4174例患者(溶栓组2102例,对照组2072例),其中9项于近5年内发表。
- 主要终点:90天极好功能预后(mRS 0-1)RR 1.22(95%CI 1.14-1.31);良好功能预后(mRS 0-2)RR 1.12(95%CI 1.06-1.18)。
- 90天全因死亡率无差异:RR 1.13(95%CI 0.93-1.38)。
- 症状性颅内出血风险增加:RR 2.44(95%CI 1.45-4.09)。
- 绝对效应:额外获得1例良好功能预后需治疗12-16例(NNT 12-16);额外发生1例症状性颅内出血需伤害62例(NNH 62)。
证据类型、等级与局限
- 证据类型为系统评价与荟萃分析,纳入14项RCT。
- 采用Cochrane Risk of Bias 2工具评估偏倚风险,随机效应模型合并RR和均数差及95%CI。
- 局限性:原文未明确列出,但纳入研究均为RCT,部分研究为开放标签设计(原文未提及具体设计细节)。
对床旁实践的改变
- 支持对发病4.5小时或更长时间、经适当影像筛选的急性缺血性卒中患者考虑静脉溶栓,以改善功能预后。
- 溶栓前需与患者或家属沟通症状性颅内出血风险增加(NNH 62),并做好溶栓后出血监测。
- 不适用于未经影像筛选的超时间窗患者(原文强调适当影像筛选)。
- 原文未提及具体影像筛选方法,临床实施需参考相关指南。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Intravenous thrombolysis (IVT) is an established therapy for acute ischemic stroke when administered within 4.5 hours of symptom onset. However, many patients present beyond this window or with unknown onset, and recent randomized clinical trials (RCTs) have evaluated whether imaging-selected patients may benefit from thrombolysis in the extended window.
OBJECTIVE: To evaluate the functional and safety outcomes associated with IVT administered 4.5 hours or more after stroke onset.
DATA SOURCES: PubMed, Embase, and Cochrane Central Register of Controlled Trials were systematically searched from database inception through March 3, 2026.
STUDY SELECTION: RCTs enrolling adults with acute ischemic stroke treated with IVT 4.5 hours or more after symptom onset were included. Trials comparing thrombolysis with placebo or standard medical care and reporting functional or safety outcomes were eligible.
DATA EXTRACTION AND SYNTHESIS: Data were extracted independently by 2 reviewers following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Risk ratios (RRs) and mean differences with 95% CIs were pooled using random-effects models. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool.
MAIN OUTCOMES AND MEASURES: Primary outcomes were excellent functional outcome (modified Rankin scale scores of 0-1 at 90 days), good functional outcome (modified Rankin scale scores of 0-2 at 90 days), all-cause 90-day mortality, and symptomatic intracerebral hemorrhage (ICH).
RESULTS: Fourteen RCTs including 4174 patients (2102 in the thrombolysis group and 2072 in the control group) were analyzed, 9 of which were published within the past 5 years. IVT was associated with a higher likelihood of excellent functional outcome (RR, 1.22; 95% CI, 1.14-1.31) and good functional outcome (RR, 1.12; 95% CI, 1.06-1.18) at 90 days. Mortality did not differ between groups (RR, 1.13; 95% CI, 0.93-1.38), but thrombolysis was associated with an increased the risk of symptomatic ICH (RR, 2.44; 95% CI, 1.45-4.09). Absolute treatment effects corresponded to a number needed to treat of 12 to 16 for an additional favorable outcome and a number needed to harm of 62 for symptomatic ICH.
CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis of 14 RCTs, IVT administered beyond 4.5 hours after stroke onset was associated with improved functional outcomes despite an increased risk of symptomatic ICH, supporting extension of thrombolytic therapy beyond the conventional treatment window in appropriately imaging-selected patients.
参考来源
- Patel S, Nischal SA, Kale KM, et al. Intravenous Thrombolysis Beyond the Conventional Time Window for Acute Ischemic Stroke: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2026. PMID: 42560675. doi:10.1001/jamanetworkopen.2026.26990
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。